FOXO1/3 and PTEN depletion in granulosa cells promotes ovarian granulosa cell tumor development

Molecular Endocrinology

Volumn 29, Issue 7, 2015, Pages 1006-1024

  Liu, Zhilin ^a   Ren, Yi A ^a   Pangas, Stephanie A ^a   Adams, Jaye ^a   Zhou, Wei ^b   Castrillon, Diego H ^c   Wilhelm, Dagmar ^d   Richards, Joanne S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; AROMATASE; BONE MORPHOGENETIC PROTEIN 2; CHITINASE 3 LIKE 3; FOLLITROPIN RECEPTOR BINDING INHIBITOR; GONADOTROPIN; MUELLERIAN INHIBITING FACTOR; NUCLEAR RECEPTOR DAX 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; RSPO1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TESTIS DETERMINING FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EMX2; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXL2; TRANSCRIPTION FACTOR GATA 4; UNCLASSIFIED DRUG; WNT4 PROTEIN; WT1 PROTEIN; BETA N ACETYLHEXOSAMINIDASE; CHI3L3 PROTEIN, MOUSE; CRE RECOMBINASE; CYTOKERATIN 8; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; FOXO1 PROTEIN, MOUSE; FOXO3 PROTEIN, HUMAN; FOXO3 PROTEIN, MOUSE; INTEGRASE; LECTIN; SMAD PROTEIN; TRANSCRIPTION FACTOR SOX9;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FATE; CELL GROWTH; CELL PROLIFERATION; CELL SPECIFICITY; CELL SUBPOPULATION; CONTROLLED STUDY; FEMALE; GRANULOSA CELL; GRANULOSA CELL TUMOR; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MACROPHAGE ACTIVATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OVARY FOLLICLE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; PATHOLOGY;

MAMMALIA; MURINAE;

ADULT; ANIMALS; BETA-N-ACETYLHEXOSAMINIDASES; CARCINOGENESIS; FEMALE; FORKHEAD BOX PROTEIN O1; FORKHEAD BOX PROTEIN O3; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPINS; GRANULOSA CELL TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRASES; KERATIN-8; LECTINS; MICE, KNOCKOUT; MIDDLE AGED; MODELS, BIOLOGICAL; PTEN PHOSPHOHYDROLASE; SMAD PROTEINS; SOX9 TRANSCRIPTION FACTOR;

EID: 84936133519     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2015-1103     Document Type: Article

References (122)

1. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415–428.
2. Romero I, Bast RC Jr. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012;153:1593–1602.
3. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol. 2010; 2010:932371.
4. Lengyel E. Ovarian cancer development and metastasis. Am J Path. 2010;177:1053–1064.
5. Mullany LK, Richards JS. Minireview: animal models and mechanisms of ovarian cancer development. Endocrinology. 2012;153: 1585–1592.
6. Jamieson S, Fuller PJ. Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr Rev. 2012;33:109–144.
7. Jubb I, Kennedy KVF, Palmer N. Pathology of Domestic Animals. 4th ed. San Diego, CA: American Press; 1993.
8. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21:1180–1189.
9. Dilworth JP. Non-germ cell tumors of testis. Urology. 1991;37: 399–417.
10. Richards JS, Fan HY, Liu Z, et al. Either Kras activation or Pten loss similarly enhances the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis. Oncogene. 2012;31:1504–1520.
11. Hu Y-C, Okumura LM, Page DC. Gata4 is required for formation of the genital ridge in mice. PLoS Genet. 2013;9:e1003629.
12. Shah SP, Köbel M, Senz J, et al. Mutation of FOXL2 in granulosacell tumors for the ovary. N Engl J Med. 2009;360:2719–2729.
13. Köbel M, Gilks CB, Huntsman DG. Adult-type granulosa cell tumors and FOXL2 mutation. Cancer Res. 2009;69:9160–9162.
14. Jamieson S, Butzow R, Andersson N, et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol. 2010;23:1477–1485.
15. Kalfa N, Philibert P, Patte C, et al. Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children. Fertil Steril. 2007;87:896–901.
16. Kim JH, Yoon S, Park M, et al. Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W). Oncogene. 2011;30:1653–1663.
17. Rosario R, Araki H, Print CG, Shelling AN. The transcriptional targets of mutant FOXL2 in granulosa cell tumours. PLoS One. 2012;7:e46270.
18. Batista F, Vaiman D, Dausset J, Fellous M, Veitia RA. Potential targets of FOXL2, a transcription factor involved in craniofacial and follicular development, identified by transcriptomics. Proc Natl Acad Sci USA. 2007;104:3330–3335.
19. Moumné L, Batista F, Benayoun BA, et al. The mutations and potential targets of the forkhead transcription factor FOXL2. Mol Cell Endocrinol. 2008;282:2–11.
20. Fleming NI, Knower KC, Lazarus KA, Fuller PJ, Simpson ER, Clyne CD. Aromatase is a direct target of FOXL2:C134W in granulosacell tumors via a single highly conserved binding site in the ovarian specific promoter. PLoS One. 2010;5:e14389.
21. Rosario R, Wilson M, Cheng WT, et al. Adult granulosa cell tumours (GCT): clinicopathological outcomes including FOXL2 mutational status and expression. Gynecol Oncol. 2013;131:325–329.
22. Uhlenhaut NH, Jakob S, Anlag K, et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell. 2009;139: 1130–1142.
23. Uda M, Ottolenghi C, Crisponi L, et al. Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. Hum Mol Genet. 2004;13:1171–1181.
24. Garcia-Ortiz JE, Pelosi E, Omari S, et al. Foxl2 functions in sex determination and histogenesis throughout mouse ovary development. BMC Dev Biol. 2009;9:36.
25. Schmidt D, Ovitt CE, Anlag K, et al. The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development. 2004;131:933–942.
26. Caburet S, Georges A, L’Hôte D, Todeschini AL, Benayoun BA, Veitia RA. The transcription factor FOXL2: at the crossroads of ovarian physiology and pathology. Mol Cell Endocrinol. 2012;356: 55–64.
27. Georges A, Auguste A, Bessière L, Vanet A, Todeschini AL, Veitia RA. FOXL2: a central transcription factor of the ovary. J Mol Endocrinol. 2014;52:R17–R33.
28. Georges A, Hôte D, Todeschini AL, et al. The transcription factor FOXL2 mobilizes estrogen signaling to maintain the identity of ovarian granulosa cells. eLife. 2014;3.
29. Padua MB, Fox SC, Jiang T, Morse DA, Tevosian SG. Simultaneous gene deletion of Gata4 and Gata6 leads to early disruption of follicular development and germ cell loss in the murine ovary. Biol Reprod. 2014;91:24.
30. Bennett J, Wu YG, Gossen J, Zhou P, Stocco C. Loss of GATA-6 and GATA-4 in granulosa cells blocks folliculogenesis, ovulation, and follicle stimulating hormone receptor expression leading to female infertility. Endocrinology. 2012;153:2474–2485.
31. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A. _-Inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature. 1992;360:313–319.
32. Tao X, Sood AK, Deavers MT, et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol. 2009;114:431–436.
33. Anttonen M, Pihlajoki M, Andersson N, et al. FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells. PLoS One. 2014;9:e85545.
34. Benayoun BA, Anttonen M, L’Hôte D, et al. Adult ovarian granulose cell tumor transcriptomics: prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation. Oncogene. 2013;32:2739–2746.
35. Pangas SA, Li X, Umans L, et al. Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol Cell Biol. 2008;28:248–257.
36. Edson MA, Nalam RL, Clementi C, et al. Granulosa cell-expresed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. Mol Endocrinol. 2010;24:1251–1266.
37. Laguë MN, Paquet M, Fan HY, et al. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulose cell tumor development and progression. Carcinogenesis. 2008;29:2062–2072.
38. Boerboom D, White LD, Dalle S, Courty J, Richards JS. Dominantstable β-catenin expression causes cell fate alterations and Wnt signaling antagonist expression in a murine granulosa cell model. Cancer Res. 2006;66:1964–1973.
39. Mansouri-Attia N, Tripurani SK, Gokul N, et al. TGFβ signaling promotes juvenile granulosa cell tumorigenesis by suppressing apoptosis. Mol Endocrinol. 2014;28:1887–1898.
40. Middlebrook BS, Eldin K, Li X, Shivasankaran S, Pangas SA. Smad1-Smad5 ovarian conditional knockout mice develop a disease profile similar to the juvenile form of human granulosa cell tumors. Endocrinology. 2009;150:5208–5217.
41. Rao MC, Midgley AR Jr, Richards JS. Hormonal regulation of ovarian cellular proliferation. Cell. 1978;14:71–78.
42. Zhou J, Kumar TR, Matzuk MM, Bondy C. Insulin-like growth factor I regulates gonadotropin responsiveness in the murine ovary. Mol Endocrinol. 1997;11:1924–1933.
43. Arraztoa JA, Kadadia R, Bondy C, Zhou J. Impaired granulosa cell proliferation in the IGF1 null ovary. The 83rd Annual Meeting of The Endocrine Society, Denver, CO, 2001 (Abstract P2–393, PP 377).
44. Zhou P, Baumgarten SC, Wu Y, et al. IGF-I signaling is essential for FSH stimulation of AKT and steroidogenic genes in granulosa cells. Mol Endocrinol. 2013;27:511–523.
45. Gonzalez-Robayna IJ, Falender AE, Ochsner S, Firestone GL, Richards JS. FSH stimulates phosphorylation and activation of protein kinase B (PKB/Akt) and serum and glucocorticoid-induced kinase (Sgk): evidence for A kinase independent signaling in granulose cells. Mol Endocrinol. 2000;14:1283–1300.
46. Baumgarten SC, Convissar SM, Fierro MA, Winston NJ, Scoccia B, Stocco C. IGF1R signaling is necessary for FSH-induced activation of AKT and differentiation of human cumulus granulosa cells. J Clin Endocrinol Metab. 2014;99:2995–3004.
47. Wayne CM, Fan HY, Cheng X, Richards JS. Follicle-stimulating hormone induces multiple signaling cascades: evidence that activation of Rous sarcoma oncogene, RAS, and the epidermal growth factor receptor are critical for granulosa cell differentiation. Mol Endocrinol. 2007;21:1940–1957.
48. Rico C, Laguë MN, Lefèvre P, et al. Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth. Carcinogenesis. 2012;33:2283–2292.
49. Higgins PA, Brady A, Dobbs SP, Salto-Tellez M, Maxwell P, Mc-Cluggage WG. Epidermal growth factor receptor (EGFR), HER2 and insulin-like growth factor-1 receptor (IGF-1R) status in ovarian adult granulosa cell tumours. Histopathology. 2014;64:633–638.
50. Andersson N, Anttonen M, Färkkilä A, et al. Sensitivity of human granulosa cell tumor cells to epidermal growth factor receptor inhibition. J Mol Endocrinol. 2014;52:223–234.
51. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999;96:857–868.
52. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004;117:421–426.
53. Kenyon C. A pathway that links reproductive status to lifespan in Caenorhabditis elegans. Ann NY Acad Sci. 2010;1204:156–162.
54. Richards JS, Sharma SC, Falender AE, Lo YH. Expression of FKHR, FKHRL1, and AFX genes in the rodent ovary: evidence for regulation by IGF-I, estrogen, and the gonadotropins. Mol Endocrinol. 2002;16:580–599.
55. Hosaka T, Biggs WH 3rd, Tieu D, et al. Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc Natl Acad Sci USA. 2004;101: 2975–2980.
56. Arden KC. FoxOs in tumor suppression and stem cell maintenance. Cell. 2007;128:235–237.
57. Tothova Z, Kollipara R, Huntly BJ, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 2007;128:325–339.
58. Paik JH, Kollipara R, Chu G, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;128:309–323.
59. Fan HY, Liu Z, Cahill N, Richards JS. Targeted disruption of Ptenin ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. Mol Endocrinol. 2008;22:2128–2140.
60. Pisarska MD, Kuo FT, Tang D, Zarrini P, Khan S, Ketefian A. Expression of forkhead transcription factors in human granulose cells. Fertil Steril. 2009;91:1392–1394.
61. Liu Z, Castrillon DH, Zhou W, Richards JS. FOXO1/3 depletion in granulosa cells alters follicle growth, death and regulation of pituitary FSH. Mol Endocrinol. 2013;27:238–252.
62. Liu Z, Rudd MD, Hernandez-Gonzalez I, et al. FSH and FOXO1 regulate genes in the sterol/steroid and lipid biosynthetic pathways in granulosa cells. Mol Endocrinol. 2009;23:649–661.
63. Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA. Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science. 2003;301:215–218.
64. Tarnawa ED, Baker MD, Aloisio GM, Carr BR, Castrillon DH. Gonadal expression of Foxo1, but not Foxo3, is conserved in diverse mammalian species. Biol Reprod. 2013;88:103.
65. Hsueh AJ, Kawamura K, Cheng Y, Fauser BC. Intraovarian control of early folliculogenesis. Endocr Rev. 2015;36:1–24.
66. Kawamura K, Cheng Y, Suzuki N, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci USA. 2013;110:17474–17479.
67. Boerboom D, Paquet M, Hsieh M, et al. Misregulated Wnt/β-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res. 2005;65:9206–9215.
68. Lesche R, Groszer M, Gao J, et al. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis. 2002;32:148–149.
69. Polanco JC, Wilhelm D, Davidson TL, Knight D, Koopman P. Sox10 gain-of-function causes XX sex reversal in mice: implications for human 22q-linked disorders of sex development. Hum Mol Genet. 2010;19:506–516.
70. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249–264.
71. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
72. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365–386.
73. Kanthan R, Senger J-L, Kanthan S. The multifaceted granulosa cell tumours-myths and realities: a review. ISRN Obstet Gynecol. 2012;2012:878635.
74. Call EL, Exner S. Zur Kenntniss des Graafschen Follikels und des Corpus luteum beim Kaninchen. Mathematish naturwssenschaftliche Classe 1875;72:321–328.
75. Ali S, Gattuso P, Howard A, Mosunjac MB, Siddiqui MT. Adult granulosa cell tumor of the ovary: fine-needle-aspiration cytology of 10 cases and review of literature. Diagn Cytopathol. 2008;36: 297–302.
76. Young RH, Scully RE. Endocrine tumors of the ovary. Curr Top Pathol. 1992;85:113–164.
77. Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledgebased Human Protein Atlas. Nat Biotech. 2010;28:1248–1250.
78. Uhlen M. The Human Protein Atlas. 2014; version 13. Available at http://www.proteinatlas.org/. Accessed June 18, 2015.
79. Munger SC, Capel B. Sex and the circuitry: progress toward a systems-level understanding of vertebrate sex determination. Wiley Interdiscip Rev Syst Biol Med. 2012;4:401–412.
80. Lan ZJ, Xu X, Cooney AJ. Differential oocyte-specific expression of Cre recombinase activity in GDF-9-iCre, Zp3cre, and Msx2Cre transgenic mice. Biol Reprod. 2004;71:1469–1474.
81. Reddy P, Liu L, Adhikari D, et al. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science. 2008;319:611–613.
82. Färkkilä A, Koskela S, Bryk S, et al. The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors-A comparative study with inhibin B [published online March 24, 2015]. Int J Cancer. doi:10.1002/ijc.29532.
83. Kusaka M, Katoh-Fukui Y, Ogawa H, et al. Abnormal epithelial cell polarity and ectopic epidermal growth factor receptor (EGFR) expression induced in Emx2 KO embryonic gonads. Endocrinology. 2010;151:5893–5904.
84. Herrera L, Ottolenghi C, Garcia-Ortiz JE, et al. Mouse ovary developmental RNA and protein markers from gene expression profiling. Dev Biol. 2005;279:271–290.
85. Silverman E, Yivgi-Ohana N, Sher N, Bell M, Elmerl S, Orly J. Transcriptional activation of sterodogenic acute regulatory protein (StAR) gene: GATA4 and CCAAT/enhancer binding protein β confer synergistic responsiveness in hormone-treated rat granulose cells and HEK293 cell models. Endocrinology. 2006;252:92–101.
86. Stocco C. Aromatase expression in the ovary: hormonal and molecular regulation. Steroids. 2008;73:473–487.
87. Anttonen M, Unkila-Kallio L, Leminen A, Butzow R, Heikinheimo M. High GATA-4 expression associates with aggressive behavior, whereas low anti-Müllerian hormone expression associates with growth potential of ovarian granulosa cell tumors. J Clin Endocrinol Metab. 2005;90:6529–6535.
88. Färkkilä A, Andersson N, Bützow R, et al. HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study. Cancer Med. 2014;3:526–536.
89. Mork L, Maatouk DM, McMahon JA, et al. Temporal differences in granulosa cell specification in the ovary reflect distinct follicle fates in mice. Biol Reprod. 2012;86:37.
90. Zheng W, Zhang H, Liu K. The two classes of primordial follicles in the mouse ovary: their development, physiological functions and implications for future research. Mol Hum Reprod. 2014;20:286–292.
91. Zheng W, Zhang H, Gorre N, Risal S, Shen Y, Liu K. Two classes of ovarian primordial follicles exhibit distinct developmental dynamics and physiological functions. Hum Mol Genet. 2014;23: 920–928.
92. Hummitzsch K, Irving-Rodgers HF, Hatzirodos N, et al. A new model of development of the mammalian ovary and follicles. PLoS One. 2013;8:e55578.
93. Rastetter RH, Bernard P, Palmer JS, et al. Marker genes identify three somatic cell types in the fetal mouse ovary. Dev Biol. 2014; 394:242–252.
94. Gundra UM, Girgis NM, Ruckerl D, et al. Alternatively activated macrophages derived from monocytes and tissue macrophages are phenotypically and functionally distinct. Blood. 2014;123:e110–e122.
95. Mullany LK, Fan HY, Liu Z, et al. Molecular characterization of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene. 2011;30:3522–3536.
96. Richards JS, Jahnsen T, Hedin L, et al. Ovarian follicular development: from physiology to molecular biology. Recent Prog Horm Res. 1987;43:231–276.
97. Richards JS, Pangas SA. The ovary: basic biology and clinical implications. J Clin Invest. 2010;120:963–972.
98. Chu S, Rushdi S, Zumpe ET, et al. FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. Mol Hum Reprod. 2002;8:426–433.
99. Risma KA, Hirshfield AN, Nilson JH. Elevated luteinizing hormone in prepubertal transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian pathology. Endocrinology. 1997;138:3540–3547.
100. St John MA, Tao W, Fei X, et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet. 1999;21:182–186.
101. Pisarska MD, Kuo FT, Bentsi-Barnes IK, Khan S, Barlow GM. LATS1 phosphorylates forkhead L2 and regulates its transcripdoitional activity. Am J Physiol Endocrinol Metab. 2010;299:E101–E109.
102. Bentsi-Barnes IK, Kuo FT, Barlow GM, Pisarska MD. Human forkhead L2 represses key genes in granulosa cell differentiation including aromatase, P450scc, and cyclin D2. Fertil Steril. 2010; 94:353–356.
103. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction. 2002;124:601–609.
104. Visser JA, Schipper I, Laven JS, Themmen AP. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol. 2012;8:331–341.
105. Richards JS. Hormonal control of gene expression in the ovary. Endocr Rev. 1994;15:725–751.
106. Richards JS. Perspective: the ovarian follicle–a perspective in 2001. Endocrinology. 2001;142:2184–2193.
107. Prunskaite-Hyyryläinen R, Shan J, Railo A, et al. Wnt4, a pleiotropic signal for controlling cell polarity, basement membrane integrity, and antimüllerian hormone expression during oocyte maturation in the female follicle. FASEB J. 2014;28:1568–1581.
108. Vainio S, Heikkilä M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. Nature. 1999;397:405–409.
109. Ottolenghi C, Pelosi E, Tran J, et al. Loss of Wnt4 and Foxl2 leads to female-to-male sex reversal extending to germ cells. Hum Mol Genet. 2007;16:2795–2804.
110. Miyamoto N, Yoshida M, Kuratani S, Matsuo I, Aizawa S. Defects of urogenital development in mice lacking Emx2. Development. 1997;124:1653–1664.
111. Taylor HS, Fei X. Emx2 regulates mammalian reproduction by altering endometrial cell proliferation. Mol Endocrinol. 2005;19: 2839–2846.
112. Okamoto J, Kratz JR, Hirata T, et al. Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients. Clin Lung Cancer. 2011;12:237–244.
113. Bilandzic M, Chu S, Farnworth PG, et al. Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. Mol Endocrinol. 2009;23:539–548.
114. Bilandzic M, Chu S, Wang Y, et al. Betaglycan alters NFKB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells. Mol Endocrinol. 2013;27:466–479.
115. Lewis KA, Gray PC, Blount AL, et al. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature. 2000;404:411–414.
116. Pangas SA. Regulation of the ovarian reserve by members of the transforming growth factor β family. Mol Reprod Dev. 2012;79: 666–679.
117. Parma P, Radi O, Vidal V, et al. R-Spondin1 is essential in sex determination, skin differentiation and malignancy. Nat Genet. 2006;38:1304–1309.
118. Bittinger S, Alexiadis M, Fuller PJ. Expression status and mutational analysis of the PTEN and PI3K subunit genes in ovarian granulosa cell tumors. Int J Gynecol Cancer. 2009;19:339–342.
119. Mullany LK, Liu Z, Wong KK, et al. Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases. Mol Endocrinol. 2014;28:127–137.
120. He CH, Lee CG, Dela Cruz CS, et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α 2. Cell Rep. 2013; 4:830–841.
121. Libreros S, Garcia-Areas R, Iragavarapu-Charyulu V. CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors. Immunol Res. 2013;57:99–105.
122. Liu L, Rajareddy S, Reddy P, et al. Infertility caused by retardation of follicular development in mice with oocyte-specific expression of Foxo3a. Development. 2007;134:199–209.